Navigation Links
A drug combination extends survival in refractory lung cancer patients
Date:6/2/2011

NEW YORK CITY Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1. The drug combination also broadened the reach to include a specific subset of patients, such as those resistant due to the presence of a ras mutation in their cancer. The study was published in the June issue of Cancer Prevention Research.

"Erlotinib has been found to be most effective in women of Asian descent who are never smokers with bronchioalveolar carcinoma, and who tend to have activating mutations of the epidermal growth factor receptor," said Ethan Dmitrovsky, M.D., an Associate Scientific Director of the Samuel Waxman Cancer Research Foundation and a senior author on the study. "None of the patients in our study fit that demographic profile."

In fact, the patients in the cohort who exhibited the greatest response included non-Asian men who were smokers. Advanced lung cancer patients with refractory disease have a survival of four months or less with traditional chemotherapy. The results of the study showed a median survival of five and a half months and longer. Three patients from the trial are now living two to four years beyond the expected average.

The study's results were recently duplicated by a group of MD Anderson scientists, noted Konstantin Dragnev, M.D., who led this trial and is an associate professor at Dartmouth Medical School, in Hanover, N.H.

The most exciting part of the research, which was funded in part by the Samuel Waxman Cancer Research Foundation, "is that scientists were able to make a dent in the ras mutation subset of patients," said Dmitrovsky, who is a professor at Dartmouth Medical School. "This area is an unmet medical need. These are often times the most difficult lung cancers to treat."

"This study gives hope to a large group of lung cancer patients who currently have very few options," said Linda Wenger, the Executive Director of Uniting Against Lung Cancer. "It's critical for nonprofit foundations to continue supporting research in underserved areas to bring new ideas to the clinic."


'/>"/>

Contact: Jenny Song
jsong@waxmancancer.org
646-398-5277
Samuel Waxman Cancer Research Foundation
Source:Eurekalert

Related biology news :

1. Old stain in a new combination
2. Diabetes drug kills cancer stem cells in combination treatment in mice
3. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
4. Study: Grass, fungus combination affects ecology
5. Grape news: New treatment combination safe alternative to sulfur dioxide
6. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
7. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
8. Combination therapy reduced HER2-positive breast cancers
9. Killing drug-resistant melanoma requires combination therapy
10. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
11. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):
(Date:6/19/2017)... ... 2017 , ... Tunnell Consulting has been solving the most complex ... challenges faced by life sciences, biotech and pharmaceuticals companies today is in interpreting the ... , who is well known in the industry and brings significant high-level expertise to ...
(Date:6/16/2017)... , ... June 16, 2017 , ... CTNext , ... Innovation Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , Nine ... to a panel of judges for an opportunity to secure $10,000 awards to help ...
(Date:6/15/2017)... ... 15, 2017 , ... angelMD announced the closure of a ... angelMD’s SVP of Corporate Development, served as the syndicate leader for this first ... Saranas’ recently announced $4 million Series B financing round. , Saranas is working ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board ... announces that they’re co-hosting a delegation from Thailand at BIO 2017 in San ... industry gathering in the world, regroups more than 1,100 biotech companies, academic institutions, ...
Breaking Biology Technology: